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SUMMARY
Background
Eosinophilic oesophagitis is a clinicopathological disease affecting both
children and adults that is characterized by symptoms of gastro-oeso-
phageal reﬂux disease (feeding refusal, vomiting, heartburn, dysphagia
and food impaction) and dense oesophageal eosinophilia both of which
are unresponsive to proton pump inhibition.
Aim
To present a review of the recent literature examining the pathogenesis
and treatments of eosinophilic oesophagitis.
Methods
We performed a PubMed search for eosinophilic oesophagitis, pathogen-
esis and treatments.
Results
Translational and basic studies suggest that this disease is sparked by
food or by aeroallergens. To date, effective treatments include systemic/
topical corticosteroids, speciﬁc food elimination or an elemental diet.
While several studies identiﬁed oesophageal strictures as potential com-
plications of unbridled eosinophilia, the natural history of the disease is
still not certain. Recent studies suggest a role for interleukin-5 and
eotaxin-3 in the pathogenesis of eosinophilic oesophagitis and suggest
an impact of future targeted therapeutic agents.
Conclusions
Eosinophilic oesophagitis represents a immune-mediated disease of
undetermined pathogenesis. While many patients develop clinicopatho-
logical ﬁndings following ingestion of foods, others do not. Natural his-
tory studies will be critical to deﬁning future treatment paradigms.
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Introduction
When Paul Ehrlich ﬁrst identiﬁed the eosinophil –
named for Eos, the Greek goddess of dawn – in 1879,
little could he know that the questions posed by this cell
would still intrigue scientists more than a century later.
The function of the eosinophil in health remains ambi-
guous and with the increasing recognition of eosinophi-
lic inﬁltrates in many gastrointestinal diseases, its
mystery in pathology is slowly being addressed. Indeed,
we stand at the dawn of understanding one of these dis-
eases, eosinophilic oesophagitis (EoE). Within the last
5 years, the literature focusing on EoE increased dra-
matically thus expanding knowledge of this enigmatic
disease. This review focuses on clinical features, patho-
genesis and treatments of EoE in adults and children.
Deﬁnition
Eosinophilic oesophagitis is deﬁned as a clinicopatho-
logical disease characterized by oesophageal symptoms
and dense oesophageal eosinophilia both of which per-
sist despite prolonged treatment with proton pump
inhibitors (PPI). Eosinophilic inﬂammation is absent in
the stomach, small intestine and colon. Importantly,
eosinophilic inﬂammation of the oesophagus has been
identiﬁed in patients with gastro-oesophageal reﬂux
disease (GERD) but the range of epithelial eosinophilia
is not certain.
1
Epidemiology
Previously considered obscure, the startling prevalence
of EoE has reached epidemic proportions. But is this a
true rise in incidence or simply increased disease
awareness? Noel et al. provided the ﬁrst paediatric
demographic data for EoE when they reported a four-
fold increase in prevalence among children from the
Midwest (US) from 2000 to 2003.
2 With the purpose of
gathering adult demographic data, Straumann and
Simon prospectively followed adult patients with EoE
in central Switzerland; during a 16-year period, the
prevalence increased from two per 100 000 inhabitants
to 27 patients per 100 000 inhabitants, with an aver-
age annual incidence of 1.4.
3 Both North American
and European studies were conducted in demographi-
cally stable areas and recording practices were consis-
tent indicating a measurable increase in EoE cases, not
just an enhanced disease awareness.
Many non-infectious, inﬂammatory gastrointestinal
diseases are considered diseases of ‘western’ civiliza-
tion, and EoE likewise falls into this category. More
than 100 adults from all continents except Africa have
been recently reported.
4–6 EoE occurs in all age groups
but symptoms typically appear either in the early
childhood, adolescence or before fourth decade of life.
Males are more frequently affected with >70% of
reported cases occurring in men.
7
Presenting symptoms
Presenting symptoms in EoE vary, depending on
patient’s age. Adults typically present with dysphagia
and food impaction.
8, 9 In a private practice setting,
Desai et al. found that 17 of 31 adults presenting with
food impaction showed clinicopathological ﬁndings
consistent with a diagnosis of EoE.
10 Additionally,
they determined that all 17 patients with EoE com-
plained of dysphagia lasting from a few seconds to
several hours. Similar ﬁndings were recognized in
other large adult series.
4–6
Children with EoE show a wider variety of symp-
toms, such as abdominal pain, chest pain, food impac-
tion, failure to thrive, vomiting and GERD-like
symptoms which are recalcitrant to acid blockade.
11–16
Such a broad spectrum of symptoms can be explained
by oesophageal dysmotility that is difﬁcult for chil-
dren to clearly translate.
Natural history
Little is known about long-term outcomes of patients
with EoE but evidence to date suggests that EoE is a
chronic disease (personal communications and obser-
vations). Most affected adults recall a history of upper
intestinal discomfort during childhood that was
thought to be due to GERD or a functional cause. In
retrospect, this was likely due to eosinophilic oesopha-
geal inﬂammation.
Isolated oesophageal strictures or pan oesophageal
narrowing are the only complications reported to
date.
17 When this narrowing encompasses the length of
the oesophagus, it is termed the ‘small caliber esopha-
gus’, a ﬁnding probably resulting from long-standing
eosinophilic inﬂammation with collagen deposition,
ﬁbrous remodelling. In the longest follow-up to date
(11.5 years), Straumann et al. found strictures in 13 of
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6 Strictures are often resistant to medical
intervention, thereby underscoring their ﬁbrotic nature.
Strictures are uncommon in children suggesting that
this complication requires years of unbridled eosino-
philic inﬂammation.
Even though strictures are the only known lasting
complication, EoE can otherwise exert a marked
impact on patient’s daily life. In a prospective observa-
tional study of 30 adult EoE patients, Straumann et al.
found that daily activities of over half of patients were
negatively impacted by EoE. In all but one patient,
dysphagia occurred on a regular basis.
6 No case of
oesophageal carcinoma has been reported but long-
term follow-up is required to conﬁrm this.
An interesting subset of patients has intense oeso-
phageal eosinophilia but no symptoms referable to the
oesophagus. Upper endoscopic analysis was performed
for bleeding or other non-oesophageal complaints and
revealed endoscopic evidence of oesophageal inﬂam-
mation and histological ﬁndings of signiﬁcant oeso-
phageal epithelial eosinophilia (personal observation
and communications). The exact meaning of this ﬁnd-
ing is still uncertain; these patients could have early
stages of EoE and will manifest symptoms eventually
or could have experienced an incidental momentary
exposure to an allergen leading to acute oesophageal
inﬂammation. More longitudinal studies will be
required to determine the correct treatment and fol-
low-up of this group of patients.
Endoscopic ﬁndings
During oesophageal endoscopy, a heterogeneous mix
of abnormalities are found including subtle reddish,
longitudinal furrows, white nodule- or plaque-like
exudates that mimic topical anaesthetic spray or fun-
gal infections, transient or ﬁxed corrugated rings,
cre ˆpe-paper mucosa due to a loss of the mucosal elas-
ticity and strictures of variable length.
4, 10, 17, 18–31
Whitish exudates (see Figure 1a; representing eosino-
philic abscesses) and longitudinal furrowing occur sec-
ondary to local oedema and acute inﬂammation. The
cre ˆpe-paper mucosa/fragile mucosa and strictures, are
likely a consequence of the chronic eosinophilic
inﬂammation (see Figure 1b).
Histological features and diagnostic criteria
Consensus opinion as to the histological diagnostic
criteria for EoE is lacking. Most would agree that
EoE is a clinicopathological disease whose diagnosis
is made based on symptoms and characteristic histo-
logical ﬁndings (>20 eosinophils/high power ﬁeld
(HPF)) that do not respond to treatment with PPIs.
Traditionally, the ﬁnding of intraepithelial eosinoph-
ils was associated with GERD but during the last
decade, a signiﬁcant body of evidence identiﬁed that
large numbers (>20 eosinophils/HPF), eosinophilic
(a)
(b)
Figure 1. (a) Endoscopic picture of the oesophagus of a
26-year-old male patient with eosinophilic oesophagitis
(EoE), suffering from dysphagia for 1 month. The image
shows an oesophageal mucosa covered with white exu-
dates, reﬂecting a highly active eosinophilic inﬂamma-
tion. (b) Endoscopic picture from the same patient,
suffering still from dysphagia. This second endoscopy was
performed exactly 1 year later and shows a rigid and
cre ˆpe-paper-like mucosa with a laceration after a contact
with the biopsy forceps. This impressive metamorphosis
illustrates the mucosal remodelling, which occurred dur-
ing the ﬁrst year in an untreated EoE.
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along the luminal surface, basal zone hyperplasia
and increased papillary size are all features highly
suggestive of EoE in the proper clinical con-
text.
13, 27, 32 EoE exclusively involves the oesopha-
gus; gastric and duodenal biopsies are normal.
Clinical differences between EoE and GERD
Differentiating between EoE and GERD can be difﬁ-
cult.
32 Oesophageal eosinophilia can occur in patients
with GERD but the degree of eosinophilia (numbers of
eosinophils per HPF) and longitudinal extent of eosi-
nophilia (proximal to distal oesophagus) is currently
unknown. A recent case series suggests that patients
with GERD can have similar endoscopic and histologi-
cal ﬁndings similar to that seen in EoE. Ngo et al.
reported three children with GERD-like symptoms,
endoscopic ﬁndings of longitudinal furrowing, whitish
exudates and >20 eosinophils/HPF. These patients
responded both symptomatically and histologically to
PPI providing strong evidence that these clinicopatho-
logical features occurred as a result of GERD. This case
series emphasizes the importance of treating all chil-
dren suspected of having EoE with high-dose PPI
before assigning a ﬁnal diagnosis of EoE.
1
The recent translational study by Blanchard et al.
brings molecular clarity to clinical suspicions that
GERD and EoE are distinct.
33 In this study, microarray
analysis was performed on oesophageal biopsy samples
from three different patient populations: (i) patients
with abdominal symptoms and normal oesophageal
histology, (ii) patients with symptoms compatible with
GERD and (iii) patients with clinicopathological fea-
tures of EoE. Microarray analysis revealed a distinct
EoE signature panel with eotaxin-3 being identiﬁed as
the most upregulated gene. Additional basic studies
utilizing a murine model of EoE in CCR-3 null mice
provide further proof for the critical role of eotaxin-3
in the pathogenesis of this inﬂammation. Long-term
outcomes of this study will hopefully bring novel
markers and novel pharmacological interventions.
PATHOGENESIS OF EOSINOPHILIC
OESOPHAGITIS
Introduction
The exact pathogenesis of EoE is uncertain. Oesopha-
geal eosinophilia can be seen in a number of condi-
tions including infections, autoimmune diseases, acid
reﬂux disease, eosinophilic gastroenteritis or allergic/
hypersensitivity responses.
34 Translational studies
examining clinicopathological features of EoE have
not identiﬁed infectious particles in the epithelium,
have measured normal pH monitoring of the distal
oesophagus in most patients
35, 36 and have not found
evidence of autoimmune diseases. EoE only affects the
oesophagus separating it from the more diffuse eosi-
nophilia seen in eosinophilic gastroenteritis. These
facts and an increasing body of clinical and basic evi-
dence suggest that EoE is a distinct disease with a
pathogenesis related to an immune-mediated response
triggered by an exogenous allergen.
Eosinophil life cycle
Eosinophils reside predominantly in three anatomical
compartments, the bone marrow, blood vessels and
organs with mucosal surfaces. Eosinophils are born
from bone marrow progenitor stem cells and mature
to a fully granulated state before migration to vascular
spaces. This process of proliferation and maturation is
controlled by interleukin (IL)-5, IL-3 and granulocyte–
macrophage colony-stimulating factor (GM-CSF) with
IL-5 being the most speciﬁc for eosinophils. In addi-
tion to inﬂuencing selective differentiation of eosin-
ophils, IL-5 also stimulates release of eosinophils from
the bone marrow and extends their survival once in
target tissues. Mice lacking IL-5 develop a signiﬁcant
reduction in mucosal eosinophilia whereas mice over-
expressing IL-5 show markedly increased peripheral
eosinophilia.
37
Eosinophils tether, roll and diapedese as they leave
the vascular space and enter the mucosa. This stepwise
journey is orchestrated by Th2 cytokines (IL-4 and IL-
13) that pave pathways and serve as chemoattractants
providing a nidus for migration. IL-4 and IL-13 induce
expression of cell surface ligands of the b-integrin
family, such as VLA-4 on the surface of eosinophils
surface, and their counter ligands on endothelia that
include vascular cell adhesion molecule (VCAM)-1.
38
Eosinophil-speciﬁc chemoattractants, such as chemok-
ines (eotaxin-1, eotaxin-2 and eotaxin-3), leukotriene
B4 and platelet-activating factor, beckon eosinophil
migration along a gradient that is released within local
mucosal microenvironments.
39 Eotaxin is produced by
a number of different cells including resident cells
(epithelium, ﬁbroblasts) and recruited cells (macroph-
ages, eosinophils).
40, 41 Eotaxin binds to the chemokine
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coupled receptor that is primarily expressed on eosin-
ophils. Eotaxin is critical in maintaining eosinophil
homeostasis in the gut as evidenced by the fact that
eosinophils are absent from the gastrointestinal tract
in mice lacking eotaxin-1.
Potential mechanisms of inﬂammation observed
in eosinophilic oesophagitis
To date the pathogenesis of EoE is controversial. Clin-
ical observations suggest that EoE results from an
immune-mediated response to a swallowed allergen.
For instance, when an amino acid-based formula is
administered or speciﬁc food proteins are removed
from diets, a clinicopathological remission occurs. One
case report documents acute exacerbations in the
spring and fall when the exposure to known aeroaller-
gens, which may be swallowed, was most signiﬁcant.
42
Personal and/or family history of allergic diseases
including IgE-mediated food allergies, asthma, atopic
dermatitis, allergic rhinitis and drug allergy are found
in 50–91% of patients with EoE. In up to 90% of
selected populations, peripheral eosinophilia can occur.
Interestingly, up to 10% of patients with eosinophil
gastrointestinal diseases have an immediate family
member with the same disease suggesting a genetic
predisposition.
43, 44 Despite these observations, the
precise immune mechanism(s) that lead to symptoms
and epithelial eosinophilia are uncertain.
IgE or non-IgE-mediated response?
An immunoglobulin (Ig)E-dependent mechanism for
EoE is supported by clinical observations. For instance,
Spergel and co-workers showed that affected patients
have IgE sensitization to a wide variety of food inclu-
ding cow’s milk, soy, peanuts, chocolate, wheat and
egg.
12, 45, 46 In these patients, clinicopathological fea-
tures of EoE resolve with dietary restriction and an
amino acid-based formula.
However, not all patients demonstrate evidence of
IgE sensitization, i.e. normal radioallergosorbent test
(RAST) or skin prick tests. Spergel et al.
46 addressed
this issue by performing skin prick and skin patch test-
ing (SPT) in 26 children with EoE. Skin patch testing
has been used in evaluations of patients with atopic
dermatitis when seeking evidence of a delayed type
hypersensitivity response. Skin patch testing consists
of placing speciﬁc food proteins on the skin, covering
it with a small disc and taping the disc in place. About
24–48 h later, the presence or the absence of swelling
and measurement thereof is recorded. Results of this
study showed that some children with negative RAST
and skin prick testing but abnormal SPT for speciﬁc
foods (see below in Treatment). Upon removal of those
speciﬁc foods identiﬁed by SPT, most children under-
went into remission.
Participation of Th2 cytokines
The pathogenesis of eosinophilic oesophageal inﬂam-
mation has been examined in greater detail in basic
animal models. Mishra et al. developed a murine
model of oesophageal eosinophilia in which nasal and
bronchial sensitization and challenge with the ubiquit-
ous aeroallergen Aspergillus fumigatus, led to oeso-
phageal but not gastric or small intestinal
eosinophilia.
37 With the use of IL-5 and eotaxin null
mice, Mishra et al.
37 demonstrated that this eosino-
philia was IL-5-dependent and partially dependent on
eotaxin.
Because of translational studies demonstrating
increased expression of IL-13 in patients with EoE and
because IL-13 is a critical Th2 cytokine thought to
participate in other allergic diseases associated with
eosinophilia, Mishra et al. and Blanchard et al. exam-
ined the impact of IL-13 in murine systems. Direct
delivery of murine or human IL-13 into the pulmonary
tree induced oesophageal eosinophilia
47 a ﬁnding that
was blocked with antihuman IL-13 antibody,
48 and
found to be diminished in IL-13 null mice. Finally,
translational studies have shown that the affected squ-
amous epithelium is immunologically rich in Th2
milieu containing increased numbers of CD8 and CD1a
lymphocytes, mast cells extensively degranulated
eosinophils and prominent expression of IL-5 and
IL-13.
28, 49–52
Taken together, these studies support a role for Th2
cytokines in the development of oesophageal eosino-
philia. Future treatments may ﬁnd basis in targeting
speciﬁc molecules, such as IL-5, IL-13 or eotaxin-3. In
fact, the use of anti-IL-5 antibody improved clinico-
pathological features in a teenager with EoE.
53
Link between mucosal systems
Rothenberg and co-workers hypothesized that both
skin and respiratory tracts contribute to the develop-
ment of oesophageal eosinophilia. In the murine model
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phagus must be exposed to the A. fumigatus antigen
for inﬂammation to occur. If A. fumigatus is applied
only to the oesophagus or to the stomach alone, no
oesophageal eosinophilia develops.
37 The skin has also
been shown to participate in allergen sensitization in
murine oesophageal eosinophilia.
54 Mice receiving
skin sensitization to A. fumigatus develop oesophageal
eosinophilia upon inhalation of the allergen. Together
these ﬁndings provide evidence that the development
of murine oesophageal eosinophilia relies on close
relationships between the mucosal immune systems of
the oesophagus, lung and skin.
Proposed effector roles for eosinophils in
gastrointestinal disease
Previous studies document a potential role for eosin-
ophils as proinﬂammatory effector leucocytes within
mucosal target organs. Eosinophils contain a number
of biologically active components including highly
charged cationic proteins, cytokines [IL-1, IL-3, IL-4,
IL-5, IL-13, GM-CSF, transforming growth factor
(TGF)-b, tumour necrosis factor (TNF)-a, RANTES,
MIP-1 and eotaxin-1], arachadonic acid mediators and
lipid products that are associated with organ dysfunc-
tion.
35 For instance, inﬂamed oesophageal tissues con-
tain increased extracellular deposition of cationic
proteins, such as major basic protein and the stool
efﬂuent of patients with inﬂammatory bowel disease
contains increased concentrations of granule proteins
suggesting that activated eosinophils release proin-
ﬂammatory mediators at mucosal sites.
10 At concen-
trations found in human tissues, major basic protein
(MBP) can diminish tight junctional molecule expres-
sion in epithelial cells,
55 induce organ contraction,
56–
58 remodel nerves
59, 60 and stimulate mast cell and
basophil degranulation
61–63 in in vitro model systems.
While the natural history of EoE remains obscure, the
fact that some patients develop oesophageal narrowing
and strictures is of concern. Leukotriene C4 is metabo-
lized to LTD4 and LTE4 both of which posses a large
proﬁle of actions including increasing mucus secretion
and vascular permeability and stimulating smooth mus-
cle contraction. This last action is quite important
because obstructive symptoms may be related to
dynamic smooth muscle contraction.
64 Alternatively,
obstructive symptoms could occur secondary to epithe-
lial proliferation and extracellular matrix remodelling,
processes linked to eosinophil-derived TGF-b.
65, 66
TREATMENT OF EOSINOPHILIC
OESOPHAGITIS
Approach to management
No consensus exists regarding optimal treatment of
patients affected by EoE. Factors deserving considera-
tion when deciding on the best treatment for an indi-
vidual patient include the patient’s age, impact of
symptoms on quality of life, impact of treatments on
quality of life and comorbid disease(s). Effective treat-
ments for EoE include systemic
15 or topical cortico-
steroids,
52, 67–70 speciﬁc elimination diets,
46 elemental
diets
12, 71, 72 and oesophageal dilation.
6, 8
Treatment decisions require examination of the
impact that EoE has on patient’s lives and the expec-
ted long-term outcomes. As described previously, chil-
dren can present with symptoms signiﬁcant enough to
affect growth, development or lifestyle. Although the
natural history of this disease has yet to be fully deter-
mined, some patients with EoE develop oesophageal
strictures. The duration of time that is required for this
complication to develop and its potential reversibility
with non-invasive treatments are both unknown.
Thus, clinical experiences and the published litera-
ture support a stance that children with EoE should
receive nutritional or medical treatment. On the other
hand, personal experiences and clinical reports suggest
that a substantial fraction of adults beneﬁt more from
oesophageal dilation than from medical or nutritional
treatment. This must be performed with extreme cau-
tion as oesophageal rupture and shearing can occur as
a complication
73, 74 (see Figure 2).
Nutritional treatments
Two types of nutritional management demonstrate
effectiveness in the treatment of EoE. The effectiveness
of these treatments relies on the fact that speciﬁc or
dietary antigens that invoke this eosinophilic response
are removed. Kelly et al. were ﬁrst to identify the suc-
cessful impact of elemental diets on clinicopathologi-
cal features of EoE.
72 In this study, 10 children with
EoE received amino acid-based formula. At the end of
treatment, all patients had resolution of symptoms and
signiﬁcant improvement in oesophageal eosinophilia.
Likewise Markowitz et al. demonstrated the effective-
ness of an elemental diet in 51 patients with EoE.
Within 8.5 days patient’s symptoms and histopatholo-
gy improved signiﬁcantly.
71
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demonstrated the utility of SPT in identifying potential
allergenic foods.
12 SPT relies on a delayed response
(non-IgE-mediated) to an allergen. In this study, 51
children with EoE were treated with an amino acid-
based formula and all but two showed a clinical
response within 9 days and mean oesophageal eosino-
phil counts decreased from 33 to 1 per HPF. Forty-
eight of 51 patients required a nasogastric tube for
administration or the formula.
In the largest series to date, Liacouras et al., recently
reported their ﬁndings in 381 patients with EoE.
16
They identify signiﬁcant impacts of treatment with an
elemental formula and dietary restriction in children
with EoE. It should be noted that three of the above
studies originated from the same institution. Addi-
tional studies to examine the utility of SPT, quality of
life related to treatments and disease, and long-term
outcomes of medical and nutritional treatments will be
important in the future.
To summarize, the nutritional management requires
testing to identify offending food allergen(s). In close
collaboration with the consulting allergist, suspected
foods are removed from the diet and the child is fol-
lowed to see if symptoms abate and histopathology
improves. In some cases, an elemental diet formula is
required to induce a remission. Individual foods are
subsequently reintroduced into the diet, while symp-
toms and histopathology are again closely observed.
In adults, the effectiveness of elimination diet and
elemental diets has not been properly determined.
Straumann et al.
6 performed a preliminary trial, inclu-
ding six adult patients with active EoE and sensitiza-
tion to several food allergens. Patients remained on a
selective elimination diet for 6 weeks. The elimination
diet failed in reducing disease activity, as symptoms as
well as endoscopic and histopathological ﬁndings
remained unchanged (unpublished data). Whether
these ﬁndings will be conﬁrmed in future studies are
yet to be determined.
Medical treatments
Medical treatments focus on the use of corticosteroids.
Systemic corticosteroids clearly impact both symptoms
and eosinophilia as shown by Liacouras et al.i n2 1
children.
15 In an attempt to reduce the systemic side-
effects and target-affected tissues, Faubion et al. used
the gavage from a metered dose inhaler (MDI), e.g. ﬂu-
ticasone. Children sprayed actuations into the mouth
and swallowed steroid preparations to provide a theor-
etical topical application to the affected oesophageal
mucosa.
69 The mouth was closed around the MDI (no
spacer was used) and children did not eat or drink for
30 min following actuations. Results demonstrated
clinical remission in all four patients studied.
Topical steroids have been used in over 70 adults
67, 70
and children
52, 68, 69 and have shown clinicopathologi-
(a)
(b)
Figure 2. (a) Oesophagography from a 35-year-old female
patient, suffering from dysphagia for 15 years. This radio-
graph was performed immediately after an attempt to
remove an impacted food bolus by rigid oesophagoscopy
and shows a long dissection of the oesophageal wall.
Laceration, dissection and perforation are well known
complications of the inﬂammation-induced remodeling of
the oesophageal mucosa. White arrow: oesophageal
lumen; Black arrow: dissection channel. (b) CT scan from
the same patient, performed after an attempt to remove
an impacted food bolus showing a dissection of the oeso-
phageal wall. White arrow: oesophageal lumen; Black
arrow: dissection channel; White arrowhead: trachea.
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sone of 220 lg per actuation, two puffs twice a day for
2 months has been used successfully.
4 A potential side-
effect includes oesophageal candidiasis.
Other medical treatments, such as cromolyn (mast
cell stabilizer) and montelukast (leukotriene antagon-
ist) can affect symptoms (personal communications).
As mast cells in affected tissues, cromolyn may offer
an impact but no reports supporting their role have
been published. Eosinophils are rich sources of leukot-
rienes, molecules known to induce smooth muscle
contraction. Thus, montelukast was administered to 12
adults with EoE. While a clinical impact was observed
with supra-physiological doses, oesophageal eosino-
philia persisted.
75
Recently, two open-labelled studies with various
hypereosinophilic disorders (including one patient with
EoE) report beneﬁcial effects from mepolizumab, a
humanized anti-IL-5 antibody.
53, 76 As discussed pre-
viously, basic evidence supports such an approach
because murine models of allergen-induced oesophagi-
tis are IL-5-dependent and translational studies dem-
onstrate increased expression of IL-5 in the affected
human oesophageal epithelium. In this report, an adol-
escent boy with signiﬁcant upper oesophageal narrow-
ing whose symptoms were refractory to all medical
and nutritional management received mepolizumab
and developed both symptomatic and histological
remission.
53 The role of this medication in the man-
agement of adults and children with EoE awaits fur-
ther study and deﬁnition.
The ultimate goal of treatment was to provide symp-
tomatic relief, and, in the opinion of these authors, to
signiﬁcantly improve mucosal inﬂammation. As long-
term outcomes suggest that some patients develop stric-
tures, we currently provide dietary or topical steroid
treatment until symptoms resolve, and then repeat the
endoscopy to ensure that mucosal healing has occurred.
Alternative approaches include monitoring for symp-
toms and evidence of stricture (Barium swallow).
Dilation treatment
Dilation, either performed with Savary bouginage or
with balloon dilators, is an established procedure in
the treatment of stenosing oesophageal diseases. How-
ever, it is important to realize, the underlying process
is not inﬂuenced by this manoeuvre. Dilations are
often quite painful with symptoms sometimes persist-
ing for several days. Following dilation, it is critical to
re-examine the mucosa because the often rigid and
inelastic mucosa can experience longitudinal splitting,
a quite impressive ﬁnding
6 (see Figure 2). While the
risk of a deep perforation is unlikely, two cases with
perforation have been reported (see Figure 2).
77 Never-
theless, the procedure is efﬁcient and dysphagia disap-
pears usually for several months.
6 Thus, we
recommend careful dilation in patients who fail med-
ical treatment for obstructive symptoms with deﬁned
oesophageal narrowing(s).
CONCLUSION AND FUTURE DIRECTIONS
Eosinophilic oesophagitis represents a relatively new
clinicopathological disease that can mimic symptoms
and ﬁndings associated with GERD. Studies to date sug-
gest an allergic aetiology with an overriding Th2 phe-
notype. Present treatments include dietary restrictions
and corticosteroids with targeted immunomodulation as
potential new opportunities. The identiﬁcation of the
natural history and the veriﬁcation of basic knowledge
in translational studies are future goals. How many
children go on to develop oesophageal strictures? Will
non-invasive markers be able to predict eventual out-
comes? If the rhino-pulmonary tree is protected from
allergen exposure, will this impact feature of EoE? What
are the best ways to monitor for long-term complica-
tions? What is the best therapeutic approach to main-
tenance therapy? Answers to the questions will follow
as adult and paediatric gastroenterologists, allergists
and pathologists work together.
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